Acertara Partners With Vanderbilt University and NINDS To Develop Revolutionary Ultrasound Technology for Nonaddictive Pain Relief
For Immediate Release
For Immediate ReleaseAcertara Contact: Dave Dallaire
[email protected]
303.834.8413
LONGMONT, CO, January 19, 2024 – In a major advance toward nonaddictive pain management, Acertara Acoustic Laboratories proudly announces its collaboration with Vanderbilt University Institute of Imaging Sciences and the National Institute of Neurological Disorders and Stroke (NINDS). This partnership is poised to develop a focused ultrasound stimulation system: a groundbreaking and promising alternative to opioid treatments for neuropathic pain caused by stroke-related nerve damage.
Acertara, an ISO/IEC 17025:2017 accredited and ISO13485:2016 certified leader in medical ultrasound technology, brings R&D and regulatory expertise to developing and bringing this technology to market. The ultrasound system, guided by magnetic resonance imaging (MRI), is designed to target and modulate neural activity deep in the brain, providing relief for the often-debilitating sensations experienced by people who suffer from neuropathic pain.
The initiative to obviate or mitigate conventional opioid-based treatments, which offer limited relief and pose a high risk of addiction, aligns with Acertara’s commitment to developing innovative healthcare solutions through ultrasound. The development phase of this project is supported by a three-year grant from the National Institutes of Health under the HEAL (Helping to End Addiction Long-term) initiative. The initial focus will be to develop the technology necessary to overcome technical barriers historically related to transcranial ultrasound and to ready the system for a pilot clinical trial.
Levi Moore, President and CEO of Acertara, expressed enthusiasm about the venture: “This collaboration represents a significant milestone in our mission to advance ultrasound technology for new therapeutic applications. We are excited about the potential of this device to transform pain management and offer a safe, effective alternative to opioids.”
The team leading Acertara’s efforts includes G. Wayne Moore and Dr. Wilder Iglesias. Vanderbilt University Institute of Imaging Science, the grant recipient and inventor of the device, is headed by lead investigator Dr. Charles Caskey.
About Acertara: Located in Longmont, Colorado, Acertara Acoustic Laboratories is a world renowned independent acoustic measurement and calibration facility. Acertara specializes in providing advanced testing services to ultrasound OEMs, researchers, and regulatory bodies globally. The company’s portfolio includes the Acoustic Power Lab Suite, AMS software, and state-of-the-art probe testing devices like Aureon™, AmpSafe 2.0, and ATLAS™. Committed to innovation, Acertara offers advanced research, product development, and engineering design services.
For more information, visit www.AcertaraLabs.com or email [email protected]. Acertara Acoustic Laboratories LLC is a Veteran-owned and operated business.